Belgium Pharmaceutical Market Trends

Over the projection period, the cardiovascular segment is anticipated to experience significant growth. During the forecast period, factors including the rising prevalence of cardiovascular illnesses as a result of alterations in lifestyle, drug approval by regulators, scientific advancements, and rising public awareness of heart health are projected to fuel segment growth. A common class of medications used to treat cardiovascular disease includes ACE inhibitors, aldosterone inhibitors, beta-blockers, calcium channel blockers, medicines that decrease cholesterol, vasodilators, and angiotensin II receptor blockers (ARBs). The high prevalence of cardiovascular illnesses in Belgium creates a demand for medications for treatment and propels market expansion. For instance, according to the Secondary Prevention of Heart Attack and Stroke, Country Profile of Belgium study, heart attacks are responsible for roughly 12% of all fatalities in Belgium. A heart attack is the most catastrophic result of coronary heart disease (CHD), which affects an estimated 407,500 people nationwide and adds 43,000 new cases of the condition every year. Over time, it is anticipated that the burden of the disease will fuel market expansion. The market is also being driven by the growing number of research projects in the area of developing new medications. For instance, 1548 research trials on the development of a treatment for cardiovascular disorders are currently taking place in Belgium, according to ClinicalTrials.gov, which was retrieved on January 11, 2022. Thus, owing to the abovementioned factors, the market segment is expected to witness growth over the forecast period.